Treatment of nasopharyngeal carcinoma in children and adolescents: Definitive results of a multicenter study (NPC-91-GPOH)

Cancer

Volumn 104, Issue 5, 2005, Pages 1083-1089

  Mertens, Rolf ^a   Granzen, Bernd ^b   Lassay, Lisa ^a   Bucsky, Peter ^c   Hundgen, Manfred ^d   Stetter, Gunter ^d   Heimann, Gerhard ^a   Weiss, Claudia ^a   Hess, Clemens F ^e   Gademann, Gunther ^f  

^a RWTH AACHEN UNIVERSITY   (Germany)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^c UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^d Rentschler Biotechnology Laupheim ^*  (Germany)

^e UNIVERSITY OF GÖTTINGEN   (Germany)

^f OTTO VON GUERICKE UNIVERSITY   (Germany)

Author keywords

Chemotherapy; Childhood; Interferon beta; Nasopharyngeal carcinoma; Radiation therapy

Indexed keywords

CISPLATIN; FLUOROURACIL; METHOTREXATE; RECOMBINANT BETA INTERFERON;

ADOLESCENT; ADULT; ARTICLE; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER REGRESSION; CANCER RELAPSE; CANCER STAGING; CARDIOTOXICITY; CHEMOTHERAPY INDUCED EMESIS; CLINICAL TRIAL; FEMALE; FEVER; FLU LIKE SYNDROME; FOLLOW UP; HEADACHE; HEART ARRHYTHMIA; HIGH RISK PATIENT; HUMAN; HYPOTHYROIDISM; LEUKOPENIA; MAJOR CLINICAL STUDY; MALE; METASTASIS; MUCOSA INFLAMMATION; MULTICENTER STUDY; NASOPHARYNX CARCINOMA; NAUSEA; NEPHROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; RADIATION DOSE DISTRIBUTION; SCHOOL CHILD; SEPTICEMIA; TREATMENT OUTCOME; TRISMUS; XEROSTOMIA;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; COMBINED MODALITY THERAPY; FEMALE; HUMANS; INTERFERON-BETA; MALE; NASOPHARYNGEAL NEOPLASMS; NEOPLASM STAGING; RADIOTHERAPY DOSAGE;

EID: 23844434298     PISSN: 0008543X     EISSN: None     Source Type: Journal    
DOI: 10.1002/cncr.21258     Document Type: Article

References (41)

1. Baker SD, Mc Clatchey KD. Carcinoma of the nasopharynx in childhood. Otolarynol 1981;89:555-559.
2. Liebowitz D, Kieff E. Epstein-Barr virus. In: Roizman B, Whitley RJ, Lopez C, editors. The human herpes virus. New York: Raven, 1993:107-172.
3. Berberoglu S, Ilhan F, Cetindag S, Sunter O. Nasopharyngeal carcinoma in Turkish children: review of 33 cases. Pediatr Hematol Oncol. 2001;18:309-315.
4. Lombardi F, Gasparini M, Gianni C, et al. Nasopharyngeal carcinoma in childhood. Med Pediatr Oncol. 1993;10:243-250.
5. Mertens R, Granzen B, Lassay L, et al. Nasopharyngeal carcinoma in childhood and adolescence. Cancer. 1997;80:951-959.
6. Krueger GRF, Wustrow J. Current classification of nasopharyngeal carcinoma at Cologne University. In: Grundmann E, Krueger GRF, Ablashi DV, editors. Nasopharyngeal carcinoma, vol. 5. Stuttgart: Verlag, 1981:11-15.
7. Lee AWM, Foo W, Poon YF, et al. Staging of nasopharyngeal carcinoma: evaluation of N-staging by Ho and UICC/AJCC systems. Union Internationale Contre le Cancer. American Joint Committee for Cancer. Clin Oncol. 1996;8:160-166.
8. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457-481.
9. Blutters-Sawatzki R, Grathwohl J, Mertens R, Lampert F. Severe cardiotoxicity of high-dose 5-fluorouracil in combination with folinic acid, cisplatin and methotrexate in a 14-year-old boy with nasopharyngeal carcinoma (Schmincke tumor). Oncology. 1995;52:291-294.
10. Serin M, Erkal HS, Elhan AH, et al. Nasopharyngeal carcinoma in childhood and adolescence. Med Pediatr Oncol. 1998;31:498-505.
11. Uzel O, Ozger S, Sahinler I, Turkan E, et al. Nasopharyngeal carcinoma in childhood: long-term results of 32 patients. Radiother Oncol. 2001;58:137-141.
12. Wolden S, Steiherz P, Kraus DH, et al. Improved long-term survival with combined modality therapy for pediatric nasopharynx cancer. Int. J Rad Oncol. 2000;48:859-864.
13. Zubizarreta P, D'Antonio G, Raslawskl E, et al. Nasopharyngeal carcinoma in childhood and adolescence: a single-institution experience with combined therapy. Cancer. 2000; 89:690-695.
14. Ayan I, Altun M. Nasopharyngeal carcinoma in children: retrospective review of 50 patients. Int J Radiat Oncol Biol Phys. 1996;35:485-492.
15. Altun M, Fandi A, Dupuis O, et al. Undifferentiated nasopharyngeal cancer (UCNT): current diagnostic and therapeutic aspects. Int Radiat Oncol Biol Phys. 1995;32:859-877.
16. Bornkamm GW. Virologisch-serologische Diagnostik des Nasopharynxkarzinoms. In: Bornkamp GW, Wannemacher M, editors. Nasopharynx-tumoren. Munich: Urban & Schwarzenberg, 1984:15-21.
17. Niedobitek G, Young LS. Epstein-Barr virus persistence and virus-associated tumors. Lancet. 1994;343:333-335.
18. Arush MW, Stein ME, Rosenblatt E, et al. Advanced nasopharyngeal carcinoma in the young: The Northern Israel Oncology Center experience, 1973-1991. Pediatr Hematol Oncol. 1995;12:271-306.
19. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Superiority of chemoradiotherapy (CT-RT) versus radiotherapy (RT) in patients (PTS) with locally advanced nasopharyngeal cancer (NPC). Preliminary results of intergroup (0099) (SWOG8892), RTOG 8817, ECOG 2388) randomized study, [abstract no. 882]. Proceedings of the American Society of Clinical Oncology. 1996; 15:313.
20. Lee AWM, Poon YF, Foo W, et al. Retrospective analysis of 5037 patients with nasopharyngeal carcinoma treated during 1976-1985: Overall survival and patterns of failure. Int J Radiat Oncol Biol Phys. 1992;23:261-270.
21. Frommhold H, Gauwerk F. Zur Strahlenbehandlung der Epipharynxtumoren. Strahlentherapie. 1972;144:509-514.
22. Barjaktarevic ZD, Golubicic V. Undifferentiated nasopharyngeal carcinoma in children: a report of four cases. J Chemother. 1995;7:249-252.
23. Pao WJ, Hustu HO, Douglass EC, et al. Pediatric nasopharyngeal carcinoma: long term follow-up of 29 patients. Int J Radiat Oncol Biol Phys. 1989;17:299-305.
24. Al-Sarraf M, LeBlanc M, Giri PGS, et al. Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III Randomized Intergroup Study 0099. J Clin Oncol. 1998;16:1310-1317.
25. Douglass EC, Fontanesi J, Ribeiro RC, Hawkins E. Improved long-term disease-free survival in nasopharyngeal carcinoma (NPC) in childhood and adolescence: a multi-institution treatment protocol, [abstract no. 1470]. Proceedings of the American Society of Clinical Oncology. 1996;15:46.
26. Mertens R, Lassay L, Heimann G. [Combined treatment of nasopharyngeal cancer in children and adolescents-concept of a study.] Klin Padiatr. 1993;205:241-248.
27. Ahern V, Jenkin D, Banerjee D, et al. Nasopharyngeal carcinoma in the young. Clin Oncol. 1994;16:24-30.
28. Mertens R, Karstens JH, Ammon J, et al. Bisherige Erfahrungen der Interferontherapie an 7 Patienten mit NPC. In: Wannenmacher M, editor. Nasopharynxtumoren. Munich: Urban & Schwarzenberg, 1984:188-193.
29. Tsukuda M, Sawaki S, Yanoma S. Suppressed cellular immunity in patients with nasopharyngeal carcinoma. J Cancer Res Clin Oncol. 1993;120:115-118.
30. De-En H, Ling XS, Hu J, et al. The effects of radiotherapy on the immune system of patients with nasopharyngeal carcinoma. Brit J Radiol 1988;61:305-308.
31. Tamura S, Yamazaki A, Kunimoto M, et al. [Impaired long-term T cell immunity to Epstein-Barr virus in patients with nasopharyngeal carcinoma.] Jpn J Cancer Res. 1992;83:445-449.
32. Tan GL. [A study of T-lymphocyte subsets, IL-2 production and IL-2 receptor expression in peripheral blood lymphocytes in patients with nasopharyngeal carcinoma.] Chung Hua Erh Pi Yen Hou Ko Tsa Chih. 1993;28:167-169.
33. Aggarwal BB, Eessalu TE, Hass PE. Characterization of receptors for human tumor necrosis factor and their regulation by interferon. Nature. 1985;318:665-668.
34. Fleischmann R, Fleischmann M. Mechanisms of interferons, antitumor agents. In: Fleischmann R, Fleischmann M, Baron S, et al., editors. Interferon-principles and medical applications. Galveston: University of Texas Medical Branch at Galveston, 1992:299-308.
35. Guang-Wu H, Sunagawa M, Jien-En L, et al. The relationship between microvessel density, the expression of vascular endothelial growth factor (VEGF), and the extension of nasopharyngeal carcinoma. Laryngoscope. 2000;110:2066-2069.
36. Wakisaka N, Wen QH, Yoshizaki T, et al. Association of vascular endothelial growth factor expression with angiogenesis and lymph node metastasis in nasopharyngeal carcinoma. Laryngoscope. 2000;109:810-814.
37. Yoshizaki T, Horikawa T, Qing-Chun R, et al. Induction of interleukin-8 by Epstein-Barr virus latent membrane protein-1 and its correlation to angiogenesis in nasopharyngeal carcinoma. Clin Cancer Res. 2001;7:1946-1951.
38. Li J, Huang G, Nong H, et al. [Expression of vascular endothelial growth factor and tumor angiogenesis correlates with biological behaviours of nasopharyngeal carcinoma.] Lin Chuang Er Bi Yan Hou Ke Za Zhi. 1999;13:343-344.
39. Qian CN, Min HQ, Lin HL, et al. Combination of angiogenesis inhibitor TNP-470 with cytotoxic drugs in experimental therapy of nasopharyngeal carcinoma. Ann Otol Rhinol Laryngol. 2000;109:641-645.
40. Sidky YA, Borden EC. Inhibition of angiogenesis by interferons: effects on tumor- and lymphocyte-induced vascular responses. Cancer Res. 1987;47:544-551.
41. Fidler F. Angiogenic heterogeneity: regulation of neoplastic angiogenesis by the organ microenvironment. J Natl Cancer Inst. 2001;93:1040-1042.